Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 235 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cream vehicle Clear all
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects

NCT00994422
View directory record Official record
Conditions
Head Lice
Interventions
Ivermectin cream, vehicle control
Drug
Lead sponsor
Topaz Pharmaceuticals Inc
Industry
Eligibility
2 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Yuma, Arizona • Los Angeles, California • Delray Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

NCT03307577
View directory record Official record
Conditions
Acne Vulgaris
Interventions
UHE-101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)

NCT03372811
View directory record Official record
Conditions
Psoriasis Vulgaris, Topical Administration
Interventions
Total coumarin (TC) cream, Vehicle
Drug
Lead sponsor
Psoriasis Research Institute of Guangzhou
Industry
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis

NCT00384098
View directory record Official record
Conditions
Psoriasis
Interventions
CTA018 cream
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Tucson, Arizona • Little Rock, Arkansas • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Sep 9, 2026, 10:22 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

NCT06958211
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
67
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients

NCT00121316
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955

NCT05206604
View directory record Official record
Conditions
Healthy
Interventions
PF-07295324, PF-07259955
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Results available

Bioequivalence Study of Two Imiquimod Cream 5%

NCT00828568
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod 5% manufactured by Taro, Aldara - Imiquimod 5%, Imiquimod Vehicle manufactured by Taro
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Gilbert, Arizona • Tempe, Arizona • Tuscon, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis

NCT02655679
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
VTP-38543, Vehicle with Transcutol®P, Vehicle without Transcutol®P
Drug · Other
Lead sponsor
Vitae Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
West Dundee, Illinois • Fort Gratiot, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

NCT02240407
View directory record Official record
Conditions
Pompe Disease
Interventions
Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, Rapamycin, saline, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream
Genetic · Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

NCT02402309
View directory record Official record
Conditions
Sjögren-Larsson Syndrome
Interventions
Active topical NS2 1% dermatologic cream, Vehicle placebo 0.0% NS2 dermatologic cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Omaha, Nebraska • Hershey, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream

NCT03308799
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
MC2-01 cream, Cal/BDP combination, Cream vehicle
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Detroit, Michigan • Fridley, Minnesota • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 3 Interventional

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

NCT00563433
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
ofloxacin, MSI-78
Drug
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1996
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

NCT01938599
View directory record Official record
Conditions
Plaque Psoriasis, Skin Diseases, Papulosquamous, Skin Diseases
Interventions
AM001 Cream, 7.5%, Placebo of AM001 Cream
Drug
Lead sponsor
AmDerma
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Miami, Florida • Fridley, Minnesota • Albuquerque, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis

NCT00778700
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo Cream, Ruxolitinib Phosphate
Other · Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
28
States / cities
Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Sep 9, 2026, 10:22 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
6 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

NCT03903822
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-06700841, Vehicle (Placebo)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

NCT06742957
View directory record Official record
Conditions
Plaque Type Psorisis
Interventions
Tapinarof Cream 1%, VTAMA®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
26
States / cities
Scottsdale, Arizona • Bryant, Arkansas • Dublin, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris

NCT03433378
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin cream, 0.05%, RETIN-A® (tretinoin) cream, 0.05%, Vehicle of the test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of Econazole Foam 1% in Athlete's Foot

NCT00768599
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot
Interventions
Econazole Nitrate Cream 1%, Econazole Nitrate Foam 1%, Vehicle Foam
Drug
Lead sponsor
AmDerma
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
San Diego, California • Clinton Township, Michigan • Fridley, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin

NCT00272610
View directory record Official record
Conditions
Skin Aging, Purpura
Interventions
0.4% Retinol Cream
Drug
Lead sponsor
University of Michigan
Other
Eligibility
70 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream

NCT03899064
View directory record Official record
Conditions
Photoallergy
Interventions
Induction: Application of MC2-01 Cream, irradiation, Induction: Application of MC2-01 Cream, no irradiation, Induction: Applications of MC2-01 vehicle, irradiation, Induction: Applications of MC2-01 vehicle, no irradiation, Challenge: Application of MC2-01 Cream, irradiation, Challenge: Application of MC2-01 Cream, no irradiation, Challenge: Applications of MC2-01 vehicle, irradiation, Challenge: Applications of MC2-01 vehicle, no irradiation, Challenge: Control, irradiation
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 9, 2026, 10:22 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study

NCT04269395
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
MAL Cream, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Fort Smith, Arkansas • Encinitas, California • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 9, 2026, 10:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations

NCT01039584
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
Butoconazole Nitrate Vaginal Cream, Placebo, Gynazole 1 vaginal cream
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 9, 2026, 10:22 PM EDT